Arm Holdings enters the post-earnings session with its cleanest quarter in months and a stock that has already done a lot of the work.
Q4 results, released after the close on May 6, landed ahead of expectations on both lines. Adjusted EPS came in at $0.60 against a $0.58 estimate. Revenue of $1.49 billion beat the $1.47 billion consensus. Q1 guidance pointed to adjusted EPS of $0.36–$0.44 versus the $0.36 street estimate, and sales of $1.255–$1.265 billion against the $1.250 billion forecast. The beat was real, but not dramatic — and the stock had already priced in considerable optimism, having rallied 40% over the past month to $208.84.
The positioning picture is genuinely interesting here, because short sellers have not capitulated. Short interest runs at 11.5% of the free float — a meaningful level for a large-cap semiconductor name — and the trend over April was broadly stable, with the count hovering near 15.7–16.0 million shares. Availability in the lending market is at roughly 200%, suggesting borrow supply is adequate and no squeeze mechanics are at work. Cost to borrow is cheap at 0.45%, and has actually eased about 18% over the past month from the 0.54–0.57% range seen in late March. The ORTEX short score of 59.5 — while elevated in absolute terms — has been drifting lower from a peak near 62.4 in late April, consistent with shorts beginning to cover into the rally rather than add to it. Put/call ratio at 1.17 is running fractionally below its 20-day average of 1.20 and well off the 1.35 levels seen in early April, suggesting options players have grown less defensive as the stock climbed. The overall borrow picture looks relaxed, not pressured.
The Street is divided in a way that captures the tension neatly. Most bulls have been raising targets into strength: Mizuho lifted its price target to $255 this week, maintaining its Outperform. Wells Fargo moved its target to $220 at the end of April. Susquehanna, Evercore, and Barclays all lifted targets into the $200–$227 range through April and late March. The mean consensus target of $175 now sits well below the current price — a sign that target upgrades have not kept pace with the stock's move, or that the consensus pool includes a meaningful bear camp. Goldman Sachs maintains a Sell with a $125 target. Morgan Stanley downgraded to Equal-Weight in early April with a $150 target. That divergence matters: the stock is trading nearly 20% above the mean target, which means the bulls who raised targets are already behind the tape, and the bears remain far below it. The forward P/E at 86.5x — up more than 22 points over the past month — gives the bears their clearest entry point. EV/EBITDA at 70.8x is broadly unchanged over 30 days, but the price-to-book has expanded by more than 4.7 points to 18.2x. The bulls' case rests on ARM's guided 20% royalty revenue CAGR through FY2031, Armv9 architecture penetration, and a nascent CPU business targeting $1 billion in revenue by FY2027. Bears point to SoftBank dependency (roughly 15% of sales), the risk that royalty rate increases alienate existing partners, and a valuation that prices in near-flawless execution.
Insiders have been consistent sellers through the run-up, adding a layer of context. CEO René Haas sold shares on March 25, March 26, and April 14 at prices ranging from roughly $161 to $163 — well below Wednesday's close of $208. CFO Jason Child sold 21,280 shares at $180 on April 22. The pattern is consistent with scheduled disposal programmes rather than a directional call on the stock, and significance scores on each transaction are low. But the aggregate net 90-day value of insider sales runs to roughly $13.6 million. Executives have been taking money off the table throughout the rally.
The two most recent earnings prints reinforce ARM's history of upside surprises with large stock reactions. The March 24 report produced a 14.7% one-day move and a 10.5% five-day move. The February 5 print generated a 17.9% one-day move and a 16.5% five-day move. Both were positive. The May 6 result dropped after this note's price date, so the immediate market reaction remains the key read in the session ahead. Among correlated peers, CEVA surged 35.7% on the week, GFS added 24.5%, and AMKR gained 7.5% — a broad semis bid that formed the backdrop for ARM's own 5.1% weekly gain before the earnings drop.
With Q4 now confirmed and Q1 guidance in the market, the next focal point becomes whether the post-earnings tape absorbs the beat cleanly or whether the 40% pre-earnings run invites sell-the-news activity from a short base that, at 11.5% of float, has plenty of room to either cover or add.
See the live data behind this article on ORTEX.
Open ARM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.